American Society of Hirudotherapy

Type 2 Diabetes Microvascular Complications (Investigational)

Investigational adjunct for microvascular complications of type 2 diabetes; one small randomized trial in neuropathy plus case reports; glycemic control and standard pharmacotherapy remain primary.

Tier C — InvestigationalInvestigational: Limited human evidence exists (small trials, case series, or pilot studies). Use is investigational and should be considered carefully under clinician guidance.Last Updated: November 12, 2026 · ASH Editorial · based on the books

Patient Summary

Is this FDA-cleared for this use?
Not FDA-cleared for diabetic microvascular complications. FDA cleared medicinal leeches only for venous congestion in microsurgical reconstruction (K040187, 2004). Use here is Tier C investigational with limited human evidence (one small randomized trial in neuropathy and case reports).
What evidence exists?
Tier C (investigational). One small randomized trial from Iran (Alemi 2022; 40 patients with type 2 diabetes and lower-limb neuropathy; leech therapy versus gabapentin) reported greater improvement in neuropathy symptom scores with leeches, but patients were not blinded, the trial followed them for only 45 days, and no replication was identified. Beyond it, the reports identified are a 5-patient case series (Engineer 2024), a few diabetic foot ulcer patients within a mixed clinic series, and single case reports of diabetic foot ulcers (for example Zaidi 2014). Evidence-based management of diabetic microvascular disease is multifaceted: glycemic control to an individualized HbA1c target, blood pressure under 130/80, ACE inhibitor or ARB for nephroprotection, statin therapy, foot care, retinal screening, and disease-specific interventions (gabapentinoids or duloxetine for painful neuropathy, intravitreal anti-VEGF for proliferative retinopathy). Critical safety: diabetic foot syndrome with neuropathy is a high-risk site for non-healing wounds.
Main risks
  • Bleeding from bite sites for 6 to 24 hours after detachment
  • Slow or impaired bite-wound healing in diabetic patients
  • Higher risk of local skin infection given diabetes-related impaired immunity
  • Aeromonas hydrophila infection
  • Worsening of any neuropathy-related pressure injury at the bite location
  • Allergic reaction to leech saliva
  • Catastrophic risk if a practitioner places a leech on a diabetic foot — this is contraindicated
  • Delay of evidence-based glycemic control, blood pressure management, ACE inhibitor/ARB, statin, and disease-specific therapy
Who should not consider this
  • Patients with active diabetic foot ulcer or Charcot foot
  • Patients with severe peripheral neuropathy and loss of protective sensation
  • Patients with HbA1c over 9 percent (optimize glycemic control first)
  • Patients with active retinal hemorrhage or proliferative retinopathy not yet treated
  • Patients with peripheral vascular disease and reduced ankle-brachial index
  • Patients on anticoagulants or with anemia (aspirin and clopidogrel, alone or together, are not a contraindication by themselves: tell your doctor, who starts with fewer leeches)
What to ask your clinician
  • What is my current HbA1c, blood pressure, and ankle-brachial index?
  • Have I had a retinal exam, kidney function assessment, and foot exam this year?
  • Am I on an ACE inhibitor or ARB and a statin per guideline?
  • What evidence-based therapy is available for my specific complication (neuropathy, retinopathy, nephropathy)?
  • Where exactly will the leech be placed — confirm NEVER on the foot or any insensate area?
  • What is the wound-care plan if the bite site does not heal as expected?
When to seek urgent care
  • New ulcer, blister, or breakdown of skin on the foot
  • Black, purple, or non-blanching discoloration of any toe
  • Spreading redness, warmth, pus, or red streaks at any bite or wound site
  • Fever above 38.0 C / 100.4 F or chills
  • Sudden vision change, floaters, or curtain-like visual loss
  • Symptoms of hypoglycemia or hyperglycemia not responding to usual management

What this does NOT mean

  • It does not replace glycemic control, blood pressure management, or guideline-based pharmacotherapy.
  • Leeches are not appropriate on the diabetic foot or any area with reduced sensation or perfusion.
  • It does not address retinopathy or nephropathy, both of which need specific evidence-based interventions.
  • The best evidence is one small randomized trial in diabetic neuropathy (40 patients, versus gabapentin 300 mg daily, 45 days, patients not blinded) plus case reports; it has not been replicated.

Clinical Profile

Category
Vascular
ICD-10
E11.40, E11.42, E11.51, E11.65
Safety tier
High

Evidence Summary

Microvascular complications of type 2 diabetes (peripheral neuropathy, retinopathy, nephropathy, dermopathy) are addressed primarily through glycemic control (individualized HbA1c target), blood pressure control, ACE inhibitor/ARB for nephroprotection, statin therapy, and disease-specific interventions. One small randomized controlled trial of leech therapy has been published for diabetic neuropathy (Alemi 2022: 40 patients with type 2 diabetes and lower-limb neuropathy, leech therapy versus gabapentin 300 mg/day, 45-day follow-up, patients not blinded), and a case series of 5 patients with diabetic peripheral neuropathy has been reported (Engineer 2024). For other microvascular complications no controlled study was identified: the two patients with diabetic retinopathy in an uncontrolled clinic series (Farzali 2025) did not improve, and no clinical study of leech therapy for diabetic nephropathy was identified. Use is investigational only. Critical safety concerns apply: the diabetic foot with neuropathy is a high-risk site for non-healing wounds and infection, and many patients are on antiplatelet therapy, an exclusion for leech application.

What the books describe

Below is a summary of what books on hirudotherapy say about this condition. These are the authors’ observations, not a proven effect and not a promise of results. Hirudotherapy has contraindications; the decision is made by a physician.

  • Baskova and Isakhanyan do not discuss complications of diabetes affecting the small vessels (nerves, kidneys, foot) as a topic for treatment with leeches: of the diabetic complications, only diabetic retinopathy is named in the sections on live leeches (in the list of indications), while diabetic micro- and macroangiopathies are named only as an indication for the drug Piyavit (these are not live leeches)[B1].
  • On type II diabetes, the book cites an observation by Konstantinova and Stalmakov (1999) in 26 patients with obesity of varying degree: hirudotherapy was used together with other methods and, according to the description, it was possible to lower the doses of blood-sugar-lowering sulfonamides (in some patients to stop them), to normalize body weight and to improve well-being, but, as the authors of the book themselves note, the work does not state the area of application, and the number of leeches, a comparison group and the follow-up period are not named in the retelling[B1].
  • Baskova and Isakhanyan name diabetic retinopathy among the vascular diseases of the eye in which, in their words, the use of leeches is advisable: they explain this by a dehydrating action and an anti-sclerotic action, by improved microcirculation and the development of bypass vessels (collaterals), but this paragraph contains no data on patients with diabetes[B1].
  • Separately, the book describes not live leeches but the medicinal preparation Piyavit, which in the studies described was taken by mouth; the authors stress that its mechanism of action differs fundamentally from the action of leech saliva in hirudotherapy[B1].
  • Michalsen et al. (chapter “Contraindications,” Flecken and Michalsen) warn that the usually harmless leech bite can cause local complications in patients with diseases in which wound healing is impaired, for example diabetes mellitus, and advise evaluating the history carefully beforehand[B3].
  • Among the contraindications listed in the book by Baskova and Isakhanyan (their list is longer) are hemophilia, hemorrhagic diatheses, anemias and the simultaneous use of anticoagulants; Michalsen et al. (chapter 8, “Contraindications,” Flecken and Michalsen) call hemophilia and the use of anticoagulants an absolute contraindication, and in anemia, in their words, treatment involving blood loss is generally contraindicated[B1][B3].
  • In one of the clinical descriptions in the book, a 52-year-old patient with ischemic heart disease and type II diabetes had heavy bleeding from the small wounds after the first hirudotherapy session, lasting more than a day, and refused further treatment; the cause of the bleeding is not discussed in this description[B1].

Treatment specifics

How many leeches, where they are placed, how long a session lasts, and whether to repeat are clinical decisions made by a qualified provider under institutional protocol — not something to self-administer. Discuss the specifics with a clinician experienced in medicinal leech therapy. (Clinicians: where the society's reference books describe a protocol, it is shown in the clinician view — switch the audience selector in the top bar to “Clinician”.)

Key Trials

  1. Alemi F et al. (2022), n=40 · Trad Integr Med · DOI 10.18502/tim.v7i4.11488

Contraindications

  • Hemophilia or another bleeding disorder
  • Taking anticoagulants (blood thinners such as warfarin or heparin)
  • Anemia or suppressed blood formation
  • Low blood pressure, shock, collapse or fainting
  • Severe wasting (cachexia)
  • Intolerance of leeches or a history of severe allergic reactions
  • Pregnancy
  • Stomach or duodenal ulcer, erosive gastritis
  • Acute infectious disease or high fever
  • Severe unstable illness, markedly weakened immunity (for example during chemotherapy) or HIV infection
  • Drinking alcohol at the time of treatment
  • No consent from the patient
  • Active deep vein thrombosis (acute phase)
  • Critical limb ischemia (ABI <0.4)
  • Active diabetic foot ulcer or Charcot foot
  • Severe peripheral neuropathy without protective sensation
  • HbA1c >9% (optimize glycemic control first)
  • Active retinal hemorrhage or proliferative retinopathy

Related Conditions

References

  • [B1]

    Баскова И.П., Исаханян Г.С. Гирудотерапия. Наука и практика [Hirudotherapy: Science and Practice]

    Москва: Монолит(2004)https://search.rsl.ru/ru/record/01007959553

    Monograph in Russian, 506 pp., ISBN 5-89527-058-1. Chapter 15: sensation at the bite, length of the session; secretion kininases and pain.

  • [B3]

    Michalsen A., Roth M., Dobos G. Medicinal Leech Therapy

    Stuttgart — New York: Thieme(2007)https://books.google.com/books?vid=ISBN9781588905635

    ISBN 978-3-13-143581-1 / 978-1-58890-563-5. Chapter 9, p. 107: perceptions of the bite — a local dragging pain lasting around one to five minutes.

The information on this page is based on the hirudotherapy books listed under References and reflects the experience their authors describe. Sensations and results differ from person to person. This information is not medical advice, a diagnosis or a prescription, and it does not replace an examination by a physician. Do not stop or change any prescribed treatment without your physician. Hirudotherapy has contraindications.

This website provides educational information and does not constitute medical advice, diagnosis, or treatment recommendations. Medicinal leech therapy carries clinically meaningful risks and should be performed only by qualified clinicians under institutionally approved protocols. FDA 510(k) clearance for medicinal leeches is limited to specific indications; investigational and off-label discussions are labeled accordingly. For patient-specific guidance, consult a qualified healthcare provider.